Researchers uncover novel mechanism by which tumors evade cancer immunotherapies

November 10, 2017

A Ludwig Cancer Research study led by Benoit Van den Eynde, Director of Ludwig Brussels, has identified a novel mechanism by which tumors of the aggressive skin cancer melanoma can resist cancer immunotherapy. Their paper, which appears in Nature Communications, describes how an immune cell recruited to the tumor induces the programmed suicide, or apoptosis, of the killer T cells harnessed by many immunotherapies. It also identifies the specific molecular interaction responsible for this effect. That interaction—between a protein on T cells known as FAS and its ligand produced by suppressive immune cells—could be disrupted to improve the efficacy of cancer immunotherapies.

"Immunotherapy has been delivering some impressive results, but only for a fraction of patients," says Van den Eynde. "Now the million dollar question is, what can we do to improve the proportion of patients that respond to these treatments? There are a variety of mechanisms of immune resistance that operate in the . This is what we are addressing in our studies."

Researchers typically transplant tumors into genetically suitable mice to study the effects of immunotherapies. But such tumors do not reflect how cancers develop in people. To take root and grow, a tumor must evolve mechanisms over months or years to evade immune attack.

"That's what happens in clinical situations and that's what we want to model in our studies," says Van den Eynde. "If you just inject a million in a mouse to create a tumor, you do not recapitulate this process—the interplay between the host and the tumor, the immune response that starts but then gets dampened by the tumor, or the tumor's ultimate escape from that response."

To recapitulate that process, the Ludwig Brussels team engineered a mouse to express a cancer-causing gene and a cancer antigen known as P1A, but only when given a particular drug. The researchers then induced melanoma tumors in their model and evaluated the effects of a battery of immunotherapies. These included cancer vaccines against the P1A antigen, and various regimens of checkpoint blockade therapies, which unleash a T cell attack on cancer cells. None worked against the induced tumors. They then tried adoptive T cell therapy (ACT), in which T cells directed against a tumor are infused into a patient.

"To my great surprise, even injecting 10 million activated T cells specific to the P1A antigen did not affect tumor growth in this induced tumor model," says Van den Eynde. When the same induced cancer cells were transplanted into mice to generate tumors, the T cell therapy invariably cleared the transplanted tumors.

To find out why, the researchers took a look at what happened to the T cells delivered by ACT. In both induced and transplanted models, they found, T cells were flooding into the tumor and ready to combat cells. But, after that, their fates diverged significantly.

"We found that in the induced tumors, about half of the T cells were already apoptotic four days after ACT," says Van den Eynde. "This explained why they did not persist: The induced tumor behaves like a sink for these T cells. That does not happen in the transplanted tumors."

Since the in both types of tumors were the same, the researchers compared the noncancerous cells present in the induced and transplanted tumors to explore what might be causing the T cell apoptosis. One type of cell, the polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC), was present exclusively in the induced tumors. MDSCs are a family of that are known to support immune evasion in a variety of ways.

Molecular analysis of the induced tumors revealed that the PMN-MDSCs in the induced tumors express high levels of a surface protein known as FAS-ligand, which induces T cell suicide when it binds its receptor on T cells. The researchers show that depleting PMN-MDSCs from the tumors or blocking FAS-ligand binding to its receptor restored the ability of the T cells to kill induced tumors.

"This is a novel mechanism by which these suppress immune responses in tumors," says Van den Eynde. "Targeting FAS-ligand could be a good adjunct therapy to boost the effects of immunotherapeutic drugs." Such drugs, he notes, are already under development. Meanwhile, Van den Eynde and his team are already hard at work looking for the other novel mechanisms of immune suppression in their model.

Explore further: COX-2 inhibitors may reverse IDO1-mediated immunosuppression in some cancers

More information: Jingjing Zhu et al, Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes, Nature Communications (2017). DOI: 10.1038/s41467-017-00784-1

Related Stories

COX-2 inhibitors may reverse IDO1-mediated immunosuppression in some cancers

July 21, 2017
In preclinical studies, tumors that consitutively expressed the protein indoleamine 2,3-dioxygenase (IDO1) responded to the cyclooxygenase-2 (COX-2) inhibitor celecoxib (Celebrex) and had improved infiltration of certain ...

Colorectal cancers may mutate to escape immune system detection in many ways

October 30, 2017
Whole exome sequencing revealed that colorectal cancers with high mutational load (MSI-H) predominantly use "immunoediting" to escape immune surveillance while colorectal cancers with low mutational load (MSS) use oncogenic ...

Checkpoint inhibitors fire up different types of T cells to attack tumors

August 10, 2017
Cancer immunotherapies that block two different checkpoints on T cells launch immune attacks on cancer by expanding distinct types of T cell that infiltrate tumors, researchers from The University of Texas MD Anderson Cancer ...

Researchers show how a targeted drug overcomes suppressive immune cells

November 9, 2016
A Ludwig Cancer Research study shows that an experimental drug currently in clinical trials can reverse the effects of troublesome cells that prevent the body's immune system from attacking tumors. The researchers also establish ...

Targeting blood vessels to improve cancer immunotherapy

April 12, 2017
EPFL scientists have improved the efficacy of cancer immunotherapy by blocking two proteins that regulate the growth of tumor blood vessels.

Silencing cancer cell communication may reduce the growth of tumors

January 30, 2017
In several types of cancer, elevated expression of the chemokine receptor CCR4 in tumors is associated with poor patient outcomes. Communication through CCR4 may be one mechanism that cancer cells use to create a pro-tumor ...

Recommended for you

Study suggests colon cancer cells carry bacteria with them when they metastasize

November 24, 2017
(Medical Xpress)—A team of researchers working at Harvard University has found evidence that suggests a certain type of bacteria found in colon cancer tumors makes its way to tumors in other body parts by traveling with ...

Promising new treatment for rare pregnancy cancer leads to remission in patients

November 24, 2017
An immunotherapy drug can be used to cure women of a rare type of cancer arising from pregnancy when existing treatments have failed.

Researchers unravel novel mechanism by which tumors grow resistant to radiotherapy

November 23, 2017
A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development. The discovery ...

African Americans face highest risk for multiple myeloma yet underrepresented in research

November 23, 2017
Though African-American men are three times more likely to be diagnosed with multiple myeloma, a type of blood cancer, most scientific research on the disease has been based on people of European descent, according to a study ...

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.